Pharsight

Msd Merck Co patents expiration

1. Delstrigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603282 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(13 years from now)

US10842751 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 30, 2023
New Patient Population (NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 2022-08-30

Market Authorisation Date: 30 August, 2018

Treatment: Treatment of hiv-1 infection in adult patients as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to...

Dosage: TABLET;ORAL

How can I launch a generic of DELSTRIGO before it's drug patent expiration?
More Information on Dosage

DELSTRIGO family patents

Family Patents

2. Emend patents expiration

EMEND's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(3 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 17 December, 2015

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage

EMEND family patents

Family Patents

3. Pifeltro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 30, 2023
New Patient Population (NPP) Jan 27, 2025

Drugs and Companies using DORAVIRINE ingredient

NCE-1 date: 2022-08-30

Market Authorisation Date: 30 August, 2018

Treatment: For use in combination with other antiretroviral agents for the treatment of hiv-1 as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substit...

Dosage: TABLET;ORAL

More Information on Dosage

PIFELTRO family patents

Family Patents

4. Recarbrio patents expiration

Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 16, 2024
Generating Antibiotic Incentives Now (GAIN) Jul 16, 2029

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

NCE-1 date: 2028-07-16

Market Authorisation Date: 16 July, 2019

Treatment: Treatment of complicated intra-abdominal infections (ciai); Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp); Treatment of complicated urina...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

RECARBRIO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic